Impact BioMedical Inc (IBO) - Final Profit

Resilient demand for hygiene components ensures asset stability, as evidenced by the company's gross profit. The current state reflects a level of 0.00, correlating with passive income from biotech patent royalties. The financial success of Impact BioMedical Inc (IBO) is based on the effective licensing of disinfection technologies and the ability to drive scientific developments toward a commercial exit.

Net Income: impactbiomedinc.com (IBO) for 09/17/2024 - 10/29/2026

Financial and market metric breakdowns for Impact BioMedical (IBO)

- market value and analyst target forecast:
Stock Price impactbiomedinc.com|IBO - Consensus Target
- market capitalization indicators:
Market Value Impact BioMedical Inc|IBO - Total Company Value
- business book valuation details:
Net Asset Value per Share Impact BioMedical|IBO - Company Net Assets|Market Cap to Book Value Multiple impactbiomedinc.com|IBO - Company Total Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Impact BioMedical Inc|IBO - Long-Term Debt to Capital|Current Liabilities to Capital Impact BioMedical, Inc.|IBO - Company Debts|Debt to Net Assets Ratio Impact BioMedical Inc|IBO - Company Long-Term Debts|Short-Term Debt Volume Impact BioMedical|Quick Liquidity Indicator impactbiomedinc.com
- company profitability and valuation multiples indicators:
IBO - Company Net Income
Basic company analysis:impactbiomedinc.com (IBO)

This indicator reflects the actual financial return of Impact BioMedical Inc (IBO), capturing operating inflows without distortions to assess market value and asset liquidity. By analyzing the company's net income, an investor can judge the viability of the diversified biomedical ecosystem of Impact BioMedical Inc (IBO), where the synergy between antiviral developments and diabetes therapy ensures the sustainable growth of the business's innovative potential.

Direct competitors

Haleon Corp (HLN) - Net Profit|Net Income KVUE|VRNA: Final Profit|Company Net Income Jyong Biotech (MENS)|LGND - Company Net Income|Amneal Pharmaceuticals Inc - Net Income|Profit After Payment of Taxes PRGO (Perrigo Corp)|Alvotech - Net Profit|Final Profit LQDA (liquidia.com)|GLPG: Net Profit|Company Net Income ANI Pharmaceuticals Inc (ANIP)|Company Net Income MannKind Corp.|AMPH: Final Profit|Net Profit PCRX|Net Financial Result ars-pharma.com|Company Net Income Theravance Biopharma, Inc. TBPH|AQST - Net Income|SCPH - Company Net Income|Profit After Tax TECX|TNXP: Net Profit|China SXT Pharmaceuticals, Inc. (SXTC) - Net Profit|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|Net Income BioHarvest Sciences, Inc. (BHST)|Net Income EXOZ (Invizyne Technologies, Inc.)|Profit After Payment of Taxes ORMP|Entera Bio - Net Income|Final Profit HYFT|ABVC BioPharma, Inc. - Net Profit|CPIX: Company Net Income|QNTM: Net Profit|FGEN - Net Financial Result|Company Net Income Telomir Pharmaceuticals|Company Net Income Rani Therapeutics Inc RANI|Company Net Income Synergy CHC Corp (SNYR)|Net Income rallybio.com RLYB|Net Profit LEXX (Lexaria Bioscience Corp.)|Pulmatrix Corporation (PULM) - Company Net Income|Pheton - Net Profit|APM (Aptorum Group Limited) - Company Profit|LYRA: Net Profit|TNFA - Net Financial Result|YCBD (cbdMD Inc.) - Net Profit|Net Income PainReform Corp (PRFX)|Net Profit CYTO|Net Profit lipella.com (LIPO)|Company Net Income OptiNose OPTN|Pieris Pharmaceuticals Inc - Company Net Income|PROC: Net Income|Final Profit PTPI (Petros Pharma)|QLI: Net Profit|SLRN - Net Financial Result|Company Net Income TFF Pharmaceuticals, Inc.